美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

138.51

-16.5000-10.64%

盤後：138.650.1400+0.10%19:59 EDT

成交量：76.14萬

成交額：1.10億

市值：4.47億

市盈率：- -

高：154.00

開：152.69

低：138.40

收：155.01

52周最高：198.18

52周最低：32.55

股本：322.45萬

流通股本：322.45萬

量比：1.10

換手率：23.61%

股息：1.22

股息率：0.88%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

華納藥廠最新公告：子公司手性藥物公司通過美國FDA現場檢查

女職工生育休假期間，用人單位可享補助！

中国会计报

醫療保健行業動態聚焦：智能眼鏡衝擊傳統巨頭，AI製藥浪潮暗湧

FDA批准百時美施貴寶(BMY.US)TYK2抑制劑氘可來昔替尼治療活動性銀屑病關節炎成人患者

智通财经网

阿斯利康(AZN.US)兩款腫瘤藥將接受FDA專家小組審判

智通财经网

資深銀行家Ajay Pathak與Bill Reisner加盟Stifel，擔任公共金融部門董事總經理

醫療保健板塊動態：市場焦點解讀

解碼兩會保險最強音：17個關鍵詞背後的新趨勢

華東醫藥(000963.SZ)：注射用HDM2024藥品臨床試驗申請已獲得美國FDA批准

螞蟻把錢都撒給阿福，是昏招還是妙手？

和譽-B(02256)：FGFR2/3抑制劑ABSK061獲FDA授予罕見兒科疾病藥物資格認定

健康160(02656)正逐步部署「醫療數字員工」系統將持續探索OpenClaw等AI智能體在醫療健康領域的深度應用

FDA批准亞葉酸作為罕見遺傳病的首個治療藥物

环球市场播报

長春高新(000661.SZ)子公司GenSci128片獲得美國FDA孤兒藥資格認定

華海藥業(600521.SH)：製劑產品加巴噴丁膠囊獲得美國FDA批准文號

行業活動推薦：全球商業健康險創新高管實戰營

FDA單次關鍵試驗政策有望推動藥物研發管線擴張——市場評論

醫療保健板塊動態：市場焦點解讀

AMN醫療保健服務公司盤中異動早盤大幅下挫5.19%

FDA疫苗負責人將離職莫德納受到關注

环球市场播报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/LABU/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":138.51,"timestamp":1774641600000,"preClose":155.01,"halted":0,"volume":761366,"hourTrading":{"tag":"盘后","latestPrice":138.65,"preClose":138.51,"latestTime":"19:59 EDT","volume":18479,"amount":2556805.1076,"timestamp":1774655971571,"change":0.14,"changeRate":0.001011,"amplitude":0.011118},"delay":0,"changeRate":-0.10644474550029032,"floatShares":3224486,"shares":3224486,"eps":0,"marketStatus":"休市中","change":-16.5,"latestTime":"03-27 16:00:00 EDT","open":152.69,"high":154,"low":138.4,"amount":109812868.86508,"amplitude":0.100639,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":155.01,"sharesOutstanding":3074486,"nav":138.527,"aum":446679735.67,"dividendRate":0.008841,"bidAskSpread":0.001941,"preHourTrading":{"tag":"盘前","latestPrice":152.4045,"preClose":155.01,"latestTime":"09:28 EDT","volume":2353,"amount":359154.6257,"timestamp":1774618126833,"change":-2.6055,"changeRate":-0.016809,"amplitude":0.020063},"postHourTrading":{"tag":"盘后","latestPrice":138.65,"preClose":138.51,"latestTime":"19:59 EDT","volume":18479,"amount":2556805.1076,"timestamp":1774655971571,"change":0.14,"changeRate":0.001011,"amplitude":0.011118},"volumeRatio":1.097954185414582,"impliedVol":1.1558,"impliedVolPercentile":0.9363},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3224486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.097205,"shares":3224486,"dividePrice":1.2246,"high":154,"amplitude":0.100639,"preClose":155.01,"low":138.4,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":138.51,"eps":0,"divideRate":0.008841,"volume":761366,"delay":0,"ttmEps":0,"open":152.69,"prevYearClose":159.39,"prevWeekClose":142.74,"prevMonthClose":172.7,"prevQuarterClose":159.39,"fiveDayClose":142.74,"twentyDayClose":172.7,"sixtyDayClose":158.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619036811","title":"華納藥廠最新公告：子公司手性藥物公司通過美國FDA現場檢查","url":"https://stock-news.laohu8.com/highlight/detail?id=2619036811","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619036811?lang=zh_tw&edition=fundamental","pubTime":"2026-03-15 16:57","pubTimestamp":1773565026,"startTime":"0","endTime":"0","summary":"华纳药厂(688799.SH)公告称，公司全资子公司湖南华纳大药厂手性药物有限公司于2025年11月10日至14日接受了美国FDA的药品批准前检查(PAI)，近日收到FDA签发的现场检查报告(EIR)，确认检查已结束，手性药物公司通过本次现场检查。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260315/32069401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4588","LABU","688799","BK0239","BK4585"],"gpt_icon":0},{"id":"2619149631","title":"女職工生育休假期間，用人單位可享補助！","url":"https://stock-news.laohu8.com/highlight/detail?id=2619149631","media":"中国会计报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619149631?lang=zh_tw&edition=fundamental","pubTime":"2026-03-14 08:01","pubTimestamp":1773446460,"startTime":"0","endTime":"0","summary":"四川：拟发女职工生育休假期间用人单位补助3月6日，四川省人力资源和社会保障厅公布《四川省人力资源和社会保障厅等7部门关于实施女职工生育休假期间用人单位补助有关事项的通知》，正式面向社会公开征求意见，征求意见期限为2026年3月7日至3月13日。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-14/doc-inhqxfkv3552664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","XLV","BK4585","LABU","XBI","BK4581"],"gpt_icon":0},{"id":"1112041100","title":"醫療保健行業動態聚焦：智能眼鏡衝擊傳統巨頭，AI製藥浪潮暗湧","url":"https://stock-news.laohu8.com/highlight/detail?id=1112041100","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112041100?lang=zh_tw&edition=fundamental","pubTime":"2026-03-14 00:22","pubTimestamp":1773418970,"startTime":"0","endTime":"0","summary":"欧洲交易时段早盘，依视路陆逊梯卡在眼镜市场的霸主地位正面临科技巨头的挑战。伯恩斯坦分析师在研报中指出，随着智能眼镜需求升温，这家法意合资企业的技术短板逐渐暴露。尽管依视路陆逊梯卡通过与Facebook母公司合作推出的Ray-Ban Meta智能眼镜率先打开市场，但这反而为科技公司大规模进军铺平道路。伴随传统眼镜销量可能萎缩的风险，该公司股价当前下跌1.5%至207.50欧元。欧洲斯托克600医疗保健指数微升0.05%，反映市场对行业变革持审慎乐观态度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","XLV","BK4581","XBI","BK4585"],"gpt_icon":0},{"id":"2619115423","title":"FDA批准百時美施貴寶(BMY.US)TYK2抑制劑氘可來昔替尼治療活動性銀屑病關節炎成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115423","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619115423?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"百时美施贵宝(BMY.US)宣布，美国食品药品监督管理局(FDA)已批准颂狄多®(氘可来昔替尼)用于治疗活动性银屑病关节炎(PsA)成人患者。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1323610961.USD","BK4534","LU0882574055.USD","IE0002141913.USD","LU1032466523.USD","LU0985481810.HKD","LU2360032135.SGD","LU0306806265.USD","LU0456855351.SGD","LU0114720955.EUR","IE00BSNM7G36.USD","LU1868836591.USD","LU2125154778.USD","LU1670710661.SGD","BK4532","LU1430594728.SGD","BK4007","LU1883839398.USD","LU1989771016.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BMY","LU2125154935.USD","LU0237698245.USD","LU1261432733.SGD","LU1868836914.USD","LU0225771236.USD","LU1670711123.USD","LU0321505439.SGD","LU1670710588.SGD","LU1585245621.USD","BK4581","BK4588","LU0868494617.USD","LU0267386448.USD","LU1868837136.USD","LU0225284248.USD","BK4559","LU0306807586.USD","LU1093756325.SGD","LU1718418525.SGD","IE00BFXG1179.USD","LABU","LU0061475181.USD","LU2242652126.USD","LU1868836757.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU1868837300.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2619049151","title":"阿斯利康(AZN.US)兩款腫瘤藥將接受FDA專家小組審判","url":"https://stock-news.laohu8.com/highlight/detail?id=2619049151","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619049151?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"近日，FDA官网宣布将在2026年4月30日召开肿瘤药物咨询委员会(ODAC)会议。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0058720904.USD","IE00B3T34201.USD","LU2456880835.USD","LU0109394709.USD","LU2417539215.USD","LU2236285917.USD","LU1829250122.USD","BK4588","LU0889565916.HKD","LU0320765992.SGD","BK4007","LABU","LU2462157665.USD","BK4585","BK4568","AZN","LU0289739699.SGD"],"gpt_icon":0},{"id":"1165357820","title":"資深銀行家Ajay Pathak與Bill Reisner加盟Stifel，擔任公共金融部門董事總經理","url":"https://stock-news.laohu8.com/highlight/detail?id=1165357820","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165357820?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 21:07","pubTimestamp":1773320861,"startTime":"0","endTime":"0","summary":"圣路易斯，2026年3月12日——Stifel Financial Corp.今日宣布，Ajay Pathak与Bill Reisner已加入公司，担任公共金融部门的董事总经理，共同领导一项差异化的医疗保健业务。两位高管将常驻圣路易斯，凭借独特的市场服务方案，为医院和医疗系统提供资本市场及顾问解决方案，在行业复杂性日益加剧的背景下，加速Stifel公共金融平台的持续扩张。Stifel的品牌实力与深厚关系，结合Pathak先生和Reisner先生的经验与领导力，为进入该行业并在公共金融领域构建增强型产品服务提供了独特机遇。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0029874061.USD","LABU","LU0128526141.USD","XLV","XBI","BK4127","BK4585","SF","BK4581","BK4137","HCSG"],"gpt_icon":0},{"id":"1153474703","title":"醫療保健板塊動態：市場焦點解讀","url":"https://stock-news.laohu8.com/highlight/detail?id=1153474703","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153474703?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 16:30","pubTimestamp":1773304243,"startTime":"0","endTime":"0","summary":"0304 GMT——野村证券分析师指出，Celltrion今年的增长动力或将来自新一代生物类似药，而非传统主力产品。Zymfentra、Yuflyma、Vegzelma及Steqeyma等新上市生物类似药有望支撑该业绩指引，而Remsima、Truxima与Herzuma等经典产品则持续提供稳定收入。分析师补充道，这些\"新生代产品组合\"占比有望突破当前50%的水平，或将推动公司开启独立于传统旗舰产品的新盈利周期。巴黎CAC 40指数下跌0.6%，主导该指数的奢侈品板块集体下挫。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4592","LU1023059063.AUD","BK4599","IE00BBT3K403.USD","LU0170899867.USD","SG9999002224.SGD","LU0306807586.USD","XLV","LU0321505868.SGD","XBI","LU0234572021.USD","LU0306806265.USD","BK4581","LU1066051498.USD","BK4007","LU0985481810.HKD","LU0289739699.SGD","LU0868494617.USD","IE00BLSP4452.SGD","LU1883839398.USD","SG9999001176.SGD","LU1894683348.USD","BK4534","SG9999011175.SGD","IE00B19Z3B42.SGD","BK4588","BK4550","SGXZ57979304.SGD","SG9999001176.USD","LU0321505439.SGD","LU0122379950.USD","IE00BLSP4239.USD","SG9999003800.SGD","LU0225284248.USD","LABU","LU1066053197.SGD","BK4533","SG9999013999.USD","IE00B19Z3581.USD","LU0225771236.USD","PFE","IE000M9KFDE8.USD","BK4585","LU1894683264.USD","LU1057294990.SGD","SG9999002232.USD","IE0002270589.USD","LU0456855351.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2618970163","title":"解碼兩會保險最強音：17個關鍵詞背後的新趨勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2618970163","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618970163?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 08:30","pubTimestamp":1773275400,"startTime":"0","endTime":"0","summary":"　　作为“十五五”开局之年，今年的两会再次释放出强化民生保障、推动高质量发展的强烈信号，而保险业作为“社会稳定器”和“经济减震器”，持续成为政策关注的重点领域。在这一关键节点，保险业有哪些值得关注的新发展趋势？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-12/doc-inhqstes4938769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4588","BK4581","BK4585","LABU","XLV"],"gpt_icon":0},{"id":"2618944821","title":"華東醫藥(000963.SZ)：注射用HDM2024藥品臨床試驗申請已獲得美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944821","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618944821?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 19:42","pubTimestamp":1773229341,"startTime":"0","endTime":"0","summary":"HDM2024 由靶向EGFR/HER3 的双抗分子，可裂解的连接子及DNA拓扑异构酶1抑制剂细胞毒性分子组成。HDM2024 可同时阻断EGFR/HER3信号通路，能够有效的阻断肿瘤细胞增殖信号，同时向肿瘤细胞内释放毒素载荷，发挥肿瘤杀伤作用。临床前研究已证明HDM2024在靶点不同表达水平的多种实体瘤药效模型中显示出强大的抗肿瘤活性，具有良好的成药性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","LU1969619763.USD","LABU","BK0187","BK0183","BK0175","BK0196","000963","BK0132","BK0188","LU2328871848.SGD","BK4585","BK4588"],"gpt_icon":0},{"id":"2618999598","title":"螞蟻把錢都撒給阿福，是昏招還是妙手？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618999598","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618999598?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 10:09","pubTimestamp":1773194974,"startTime":"0","endTime":"0","summary":"几乎同时，蚂蚁阿福顺势推出16.8元红包活动，面向新注册用户，限时48小时。活动力度之大，在AI行业引发震动。\"取舍的结果已经清晰，健康业务\"阿福\"被赋予\"必须赢\"的战略地位，而同期推出的通用AI助手\"灵光\"更多是试水AI。蚂蚁为什么要把钱都撒给阿福？公开数据显示，阿福月活用户量已超过3000万。因此，阿福瞄准的增量市场，其实是比“轻问诊”还要更轻的“健康管理”。一方面阿福作为AI产品，还是很难摆脱幻觉和抽卡问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1772458064293015706","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0181495838.USD","AIYY","LU0128525689.USD","LU0329678337.USD","SGXZ62798434.SGD","SG9999001051.SGD","BABX","BK1615","SG9999004220.SGD","XLV","LU0651947912.USD","BK4575","ALBmain","LU1224709979.USD","BK4023","BK4565","LU2226246903.HKD","LU0577902611.USD","HBBD.SI","LABU","LU0588545730.USD","LU1481107354.HKD","XBI","LU0130103400.USD","LU1568876335.HKD","LU0672654166.SGD","LU2242644610.SGD","06688","KBAB","BABU","LU0261950983.USD","LU0327786744.USD","BABW","LU0370786039.SGD","AI","BBYY","BK1575","LU1880398554.USD","LU0949170772.SGD","BK4527","LU0608807433.USD","BABO","LU0516423091.SGD","LU0541502299.USD","LU1051769294.HKD","89988","LU0661504455.SGD","LU0738911758.USD"],"gpt_icon":1},{"id":"2618998304","title":"和譽-B(02256)：FGFR2/3抑制劑ABSK061獲FDA授予罕見兒科疾病藥物資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2618998304","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618998304?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 08:14","pubTimestamp":1773188070,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司的附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性、口服小分子FGFR2/3抑制剂ABSK061，已获得美国食品药品监督管理局授予用于治疗软骨发育不全的罕见儿科疾病药物资格认定。其口服给药方式在便捷性和治疗依从性方面具有显著优势，尤其对儿科患者而言，这使得ABSK061有望成为治疗儿童和青少年ACH患者的具有潜在价值的治疗候选药物。目前，ABSK061正在开展针对3-12岁儿童ACH患者的II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412409.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK4588","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2778985437.USD","02256","IE00BPRC5H50.USD","LABU","BK1161","LU2476274720.SGD","LU2476274308.USD","BK4585"],"gpt_icon":0},{"id":"2618100962","title":"健康160(02656)正逐步部署「醫療數字員工」系統 將持續探索OpenClaw等AI智能體在醫療健康領域的深度應用","url":"https://stock-news.laohu8.com/highlight/detail?id=2618100962","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618100962?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 06:27","pubTimestamp":1773181641,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康160 发布公告，集团依托“平台+AI智能体+运营”的一体化模式，正为医疗机构逐步部署“医疗数字员工”系统，推动以OpenClaw为代表的AI智能体在医疗场景的落地应用。未来，集团将凭借真实的医患交互场景与成熟的平台化运营能力，持续探索OpenClaw等AI智能体在医疗健康领域的深度应用，致力为股东创造长期价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159891","159819","XBI","BK4588","BK1197","BK4581","BK4585","159760","XLV","LABU","02656"],"gpt_icon":0},{"id":"2618470955","title":"FDA批准亞葉酸作為罕見遺傳病的首個治療藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2618470955","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618470955?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 21:39","pubTimestamp":1773149940,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准了一种已有数十年历史的处方维生素——亚叶酸，作为某些成人和儿童罕见遗传性疾病的首个治疗方法。　　此举是在特朗普政府数月前鼓吹亚叶酸可作为更广泛的有自闭症症状患者的潜在疗法之后做出的。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6200593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","LABU"],"gpt_icon":0},{"id":"2618319739","title":"長春高新(000661.SZ)子公司GenSci128片獲得美國FDA孤兒藥資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2618319739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618319739?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 18:38","pubTimestamp":1773139109,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 长春高新 发布公告，近日，公司子公司——长春金赛药业有限责任公司收到美国食品药品监督管理局通知，授予GenSci128片孤儿药资格认定，用于胰腺癌的治疗。本次获得孤儿药资格的认定，有助于GenSci128片用于胰腺癌的治疗在美国的后续研发和审评过程中获得一定的政策支持，包括但不限于：临床试验费用的税收抵免、免除新药申请费、上市后享有7年的市场独占权且不受专利的影响等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0239","BK0028","BK0046","BK0188","BK0057","LABU","BK0075","BK4585","BK4588"],"gpt_icon":0},{"id":"2618619935","title":"華海藥業(600521.SH)：製劑產品加巴噴丁膠囊獲得美國FDA批准文號","url":"https://stock-news.laohu8.com/highlight/detail?id=2618619935","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618619935?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 17:27","pubTimestamp":1773134836,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华海药业(600521.SH)发布公告，近日，公司收到下属子公司普霖斯通制药有限公司的通知，其向美国食品药品监督管理局(简称“美国FDA”)申报的加巴喷丁胶囊的新药简略申请(ANDA，即美国仿制药申请)已获得批准。加巴喷丁胶囊主要用于成人带状疱疹后神经痛的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","LABU","BK0185","BK0070","BK0188","BK0201","BK4585","BK4588","600521","BK0012"],"gpt_icon":0},{"id":"2618933286","title":"行業活動推薦：全球商業健康險創新高管實戰營","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933286","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618933286?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 17:12","pubTimestamp":1773133920,"startTime":"0","endTime":"0","summary":"但与美国等成熟市场相比，中国在医疗服务体系结构、支付机制、监管体系及市场化运行方面仍存在差距，商业健康险在医疗价值链中的作用仍有待加强。系统研究这些国际经验，有助于推动中国商业健康保险从“赔付型”向“服务型”转型，促进医疗服务网络建设、支付模式创新与数字化发展，为中国医疗健康体系实现高质量与可持续发展提供重要参考。　　现重点推介项目美国“破浪者-全球商业健康险创新高管实战营”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/health/2026-03-10/doc-inhqpaer6196375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4581","BK4585","XLV","XBI","BK4588"],"gpt_icon":0},{"id":"1134767323","title":"FDA單次關鍵試驗政策有望推動藥物研發管線擴張——市場評論","url":"https://stock-news.laohu8.com/highlight/detail?id=1134767323","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134767323?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 01:38","pubTimestamp":1773077902,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）新推行的单次临床试验审批政策，或将显著拓宽制药行业的研发管线。摩根大通分析师在研究报告中指出，今年二月FDA局长正式宣布新规，未来仅需一项“充分且良好对照”的研究，辅以验证性证据，即可支持创新产品的上市批准。\n尽管单次关键试验的实践并非全新举措，但分析师强调该政策的正式落地，可能促使制药企业将因减少三期临床试验所节省的成本，重新投入药物发现与临床前研究领域。从长远来看，这一转变有望逐步提升实现商业化的药物总量。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588"],"gpt_icon":0},{"id":"1184178734","title":"醫療保健板塊動態：市場焦點解讀","url":"https://stock-news.laohu8.com/highlight/detail?id=1184178734","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184178734?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 00:22","pubTimestamp":1773073374,"startTime":"0","endTime":"0","summary":"1054 ET——伯恩斯坦分析师在研报中指出，罗氏控股的乳腺癌重点候选药物giredestrant虽未达到三期临床试验主要终点，但无碍该公司制药业务的转型进程。尽管这一消息带来负面影响，分析师认为其并不会使这家瑞士药企的研发引擎脱轨。罗氏去年将五款药物从中期推进至后期试验阶段，全部位列最具潜力的研发管线，伯恩斯坦预估其峰值销售额将突破30亿瑞士法郎。此次失败的试验所针对的适应症仅占最常见乳腺癌药物市场的不足20%。罗氏股价下跌3.25%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4588","BK4585","LABU","XLV"],"gpt_icon":0},{"id":"2618448937","title":"AMN醫療保健服務公司盤中異動 早盤大幅下挫5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618448937","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618448937?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 21:59","pubTimestamp":1773064788,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日21时59分，AMN医疗保健服务公司股票出现波动，股价急速下跌5.19%。截至发稿，该股报20.17美元/股，成交量12.8682万股，换手率0.33%，振幅4.67%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。AMN医疗保健服务公司股票所在的医疗设施行业中，整体跌幅为0.49%。AMN医疗保健服务公司公司简介：AMN Healthcare Services Inc 在美国提供医疗保健劳动力解决方案和人员配备服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921594895461cce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030921594895461cce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LABU","BK4196","XLV","XBI","BK4585","BK4581","AMN"],"gpt_icon":0},{"id":"2618291116","title":"FDA疫苗負責人將離職 莫德納受到關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2618291116","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618291116?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 21:05","pubTimestamp":1773061500,"startTime":"0","endTime":"0","summary":"FDA的维奈·普拉萨德将在包括莫德纳流感疫苗和亨廷顿疗法在内的审评争议后离职，这引起了莫德纳和uniQure利益相关者的关注。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-09/doc-inhqmcpk3793675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","159646","LABU","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":199,"code":"91000000","status":"200"}]}}